Press Releases

OSLO, Norway--(BUSINESS WIRE)-- Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensors™ currently deployed in over 500 million devices, has announced the shipping of its AI Virtual Proximity Sensor™ INNER BEAUTY® on vivo’s S19 and S19 Pro smartphones. The vivo S19 series, targeted for the Chinese market, are powered by Elliptic Labs’ partners Qualcomm and MediaTek. The vivo S19 is running Qualcomm’s... (continue reading...)

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The... (continue reading...)

LONDON, 31 May. 2024 (GLOBE NEWSWIRE) -- This is the Start of Day Message for GlobeNewswire.

GlobeNewswire is operated by Notified and is designated by the FCA as an approved primary information provider.

Disclaimer

The content and accuracy of all information distributed through Notified is wholly the responsibility of the originator. Notified accepts no liability for any losses arising from reliance by any person upon the content of any announcement.

If you... (continue reading...)

Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD).... (continue reading...)

PRESS RELEASE – REGULATED INFORMATION

Mont-Saint-Guibert, Belgium, May 31, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007... (continue reading...)